Ultragenyx Pharmaceutical
RARE
288 hedge funds and large institutions have $2.16B invested in Ultragenyx Pharmaceutical in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 111 increasing their positions, 91 reducing their positions, and 65 closing their positions.
60% more call options, than puts
Call options by funds: $75.9M | Put options by funds: $47.6M
22% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 91
1.7% less ownership
Funds ownership: 99.08% → 97.37% (-1.7%)
5% less funds holding
Funds holding: 303 → 288 (-15)
12% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 65
25% less capital invested
Capital invested by funds: $2.87B → $2.16B (-$710M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$65.6M |
| 2 |
Morgan Stanley
New York
|
+$30.1M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$29.5M |
| 4 |
Millennium Management
New York
|
+$25.7M |
| 5 |
Jane Street
New York
|
+$21.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$152M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$31.1M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$29.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.9M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$22.6M |
RARE Hedge Fund Activity: Q4 2025 in Review
288 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2025, worth a combined $2.16B — down 25% from $2.87B a quarter earlier.
Sellers outnumbered buyers: 65 funds closed out of RARE and 57 opened new positions — a net loss of 8 holders — while 91 trimmed existing stakes and 111 added.
The largest buyer was Citadel Advisors, adding an estimated $65.6M. The largest seller was Fidelity Investments, cutting an estimated $152M.
- 288 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2025, down from 303 in Q3 2025.
- Funds reported $2.16B of Ultragenyx Pharmaceutical stock for Q4 2025, down 25% quarter-over-quarter.
- 57 funds opened new Ultragenyx Pharmaceutical positions in Q4 2025 and 65 closed out, a net change of -8 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2025 was Citadel Advisors, an estimated $65.6M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2025 was Fidelity Investments, an estimated $152M sold.
Based on aggregated 13F filings for Q4 2025.